Non-Small Cell Lung Cancer Clinical Trials

Innovative Therapies for Non-Small Cell Lung Cancer

If you are looking for non-small cell lung cancer treatment, Massive Bio can assist you. Our advanced artificial intelligence (AI) platform will recommend treatment options through clinical trials tailored to your specific condition. Once you submit your information, our oncology experts will review your advanced NSCLC case and contact you.

When dealing with a diagnosis of locally advanced, inoperable, or metastatic non-small cell lung cancer, it’s important to fully understand the treatment options. Our role is to link patients with a pioneering clinical trial dedicated to creating novel, targeted treatments, particularly for individuals exhibiting PD-L1 expression. These therapies are tailor-made to tackle the specific hurdles posed by metastatic or inoperable lung cancer, and they are offered free of charge to those participating in the trial.

When you register for our matching service, we’ll help you find clinical trials for free that are a good fit for your situation. Here’s how it works:

Diagnosis: Should you be diagnosed with non-small cell lung cancer, including stage 3 inoperable NSCLC or stage 4 NSCLC with a PD-L1 positive status, you might qualify for participation in innovative and promising clinical trials.

What is Non-Small Cell Lung Cancer?: Non-Small Cell Lung Cancer (NSCLC) makes up about 80-85% of all lung cancer cases and is marked by larger cancer cells than those found in small cell lung cancer. NSCLC tends to progress more slowly and is more amenable to surgical interventions, particularly in early stages. The prognosis and survival rates vary depending on the stage at which it’s diagnosed. Stage 3 lung cancer is a more advanced form, where larger tumors may have spread to nearby lymph nodes, sometimes making them inoperable. Stage 4 lung cancer, or metastatic lung cancer, is the most advanced stage, where the cancer has spread beyond the lungs to other body parts like the brain, bones, and liver, showing significant metastasis and posing greater treatment challenges. Additionally, the presence of PD-L1, a protein that can help cancer cells avoid detection by the immune system, plays a crucial role in treatment planning. Higher levels of PD-L1 in NSCLC can influence the effectiveness of certain therapies and are a key factor in selecting appropriate treatment options.

Enhancing Your Treatment Prospects with Genetic Testing: If genomic testing shows the tumor has PD-L1 expression, this clinical trial could be a great fit for you. PD-L1 protein, found on certain cancer cells, is identified through an IHC test (Immunohistochemistry test). Additionally, IHC is used to determine if a tumor has issues with DNA repair, known as Mismatch Repair (MMR) deficiency. To detect numerous small alterations in a tumor’s DNA, termed Microsatellite Instability, doctors may employ tests based on PCR (Polymerase Chain Reaction) or NGS (Next-Generation Sequencing).

What is PD-L1?: PD-L1 is a protein that acts like a secret signal on the surface of lung cancer cells. Think of it as a kind of disguise that tricks the body’s immune system into thinking the cancer cells are normal, so the immune system doesn’t attack them. When doctors test for PD-L1 in lung cancer patients, they’re looking for how much of this disguise is present. The more PD-L1 a cancer has, the better it can hide from the immune system. Knowing this helps doctors decide which treatments to use and enhance the possibility of getting targeted treatment like the ones offered in clinical trials.

Recommended biomarkers:

ALK (+): The ALK mutation involves a change in the ALK gene that leads to abnormal cell growth. This gene mutation is commonly observed in certain types of lung cancer, aiding doctors in selecting targeted therapies that specifically combat cells that have the ALK alteration.

ROS1: The ROS1 mutation is a genomic variance in the ROS1 gene, which can result in cancer due to uncontrolled cell growth. In lung cancers where a ROS1 mutation is present, it’s important for treatment as specific drugs can target and more effectively treat these mutated cancer cells.

RET: The RET mutation refers to changes in the RET gene, responsible for producing a protein that influences cell growth and survival. When mutated, the RET gene can contribute to the development of various cancers, including a subset of lung cancers. Targeted therapies that inhibit the abnormal activity of the RET mutation are considered as ground breaking treatment.

How can I find my biomarker?: Next Generation Sequencing (NGS) testing is a modern way to examine your DNA—the blueprint of your body—very closely and quickly. It reads the tiny parts of your DNA to find any changes that might cause the disease or affect how you respond to medications. Certain clinical trials require genetic testing to find out the origin of the cancer and target it directly.

Innovative Therapy: This clinical trial brings together the latest advancements in medical science and technology to target your lung cancer with precision and effectiveness.

Personalized Match: We understand that every patient is unique, and that’s why we focus on matching you with a clinical trial that aligns with your specific requirements and medical history, whether you’re dealing with non-small cell lung cancer.

Customized Guidance: Throughout your journey, our experienced clinical team will be by your side, providing support, and answering your questions about NSCLC treatments and NSCLC clinical research studies.

By signing up for our matching program, you’re taking an active role in exploring new possibilities and gaining access to an innovative therapy that can potentially transform your life.

Patients who have an ALK+, ROS1+, or RET mutation are highly likely to be eligible for this study. If you haven’t undergone an NGS test or don’t have these results, we offer a free NGS testing service for individuals diagnosed with certain conditions. This helps determine your eligibility and opens up potential treatment options for you.